A recent retrospective study of HCM patients with COVID-19 concluded that HCM patients are at increased risk of hospitalization and death from a COVID-19 infection. 

In particular, the study found that the following groups of HCM patients were at increased risk of adverse complications from COVID-19:

• patients with the obstructive form of HCM
• patients with left ventricular systolic dysfunction
• older patients
• patients who also have other high risk conditions for COVID-19 such as hypertension, diabetes, obesity or those who are smokers 

Based on this data, the researchers suggest “the need for aggressive and systematic implementation of prophylactic measures for SARS-COV-2 in patients with inherited cardiac disease.”   

At this time, such measures include vaccinations, masking, and therapeutic agents such as Paxlovid and monoclonal antibodies.

IMPORTANT NOTE:  This study finished enrollment just as COVID-19 vaccines became available. Hence, these results do not take into account the effect of vaccinations or newer COVID-19 therapeutics such as Paxlovid.